- Home
- DCI vs ROIV Comparison
DCI vs ROIV Comparison
Compare DCI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DCI | ROIV |
|---|---|---|
| Founded | 1915 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 20.7B |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DCI | ROIV |
|---|---|---|
| Price | $85.13 | $28.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $99.00 | $27.56 |
| AVG Volume (30 Days) | 471.2K | ★ 4.5M |
| Earning Date | 02-26-2026 | 02-06-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $2,844,900,000.00 | $29,053,000.00 |
| Revenue This Year | $4.58 | N/A |
| Revenue Next Year | $5.08 | $594.84 |
| P/E Ratio | $48.67 | ★ N/A |
| Revenue Growth | ★ 4.05 | N/A |
| 52 Week Low | $57.45 | $8.73 |
| 52 Week High | $112.84 | $30.33 |
Technical Indicators
Market Signals| Indicator | DCI | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 39.09 | 56.22 |
| Support Level | $82.88 | $26.94 |
| Resistance Level | $88.12 | $30.33 |
| Average True Range (ATR) | 2.03 | 0.95 |
| MACD | 0.57 | -0.12 |
| Stochastic Oscillator | 57.91 | 79.20 |
Price Performance
Historical ComparisonAbout DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.7 billion in revenue in its fiscal 2025.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.